• Murat Çap, Önder Bilge, Ferhat Işık, Cengiz Burak, Ali Karagöz, Ümit İnci, Abdurrahman Akyüz, Burhan Aslan, Bernas Altıntaş, Rojhat Altındağ, İlyas Kaya, Mehmet Şahin Adıyaman, Muhammed Süleymanoğlu, Şafak Kaya, and Erkan Baysal.
• Department of Cardiology, SBU Diyarbakır Gazi Yaşargil Education and Research Hospital, Diyarbakır, Turkey. Electronic address: murat00418@hotmail.com.
• J Electrocardiol. 2020 Nov 1; 63: 115-119.

BackgroundThe effect of favipiravir on the QTc interval during the treatment of Coronavirus Disease 2019 (COVID-19) patients is unclear. Thus, the current study objective was to evaluate any change in the QTc interval in patients who were hospitalized due to COVID-19 receiving favipiravir treatment.MethodPatients hospitalized with COVID-19 were assessed in this single-center retrospective study. 189 patients, whose diagnosis was confirmed using real-time PCR, were included in the study. The patients were divided into three groups: those using hydroxychloroquine (Group 1, n = 66), hydroxychloroquine plus favipiravir (Group 2, n = 66), and favipiravir only (Group 3, n = 57). The QTc interval was measured before treatment (QTc-B) and 48 h after (i.e., the median) starting treatment (QTc-AT).ResultsThe median age was 53 (39-66 IQR) and 97 (51%) of patients were female. The median QTc(Bazett)-change was 7 ms (p = 0.028) and 12 ms (p < 0.001) and in Group 1 and 2, respectively. In Group 3, the median QTc(Bazett)-change was observed as -3 ms and was not statistically significant (p = 0.247). In multivariable analysis, while there was a significant relationship between QTc-AT(Bazett) and hydroxychloroquine (β coefficient = 2687, 95%CI 2599-16,976, p = 0,008), there was no significant relationship with favipiravir (β coefficient = 0,180, 95% CI -6435-7724, p = 0,858). Similarly, there was a significant relationship between the QTc-AT interval calculated using the Fredericia formula and hydroxychloroquine (β coefficient = 2120, 95% CI 0,514-14,398, p = 0,035), but not with favipiravir (β coefficient = 0,111, 95% CI -6450- 7221, p = 0,911).ConclusionIn the ECG recordings received in the following days after the treatment was started in COVID-19 patients, there was a significant prolongation in the QTc interval with hydroxychloroquine, but there was no significant change with favipiravir.Copyright © 2020 Elsevier Inc. All rights reserved.

25 keywords...

hide…